Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography

Pharmazie

Volumn 61, Issue 7, 2006, Pages 586-589

  Kocyigit Kaymakcoglu, B ^a   Unsalan S ^a   Rollas, Sevim ^a  

^a MARMARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONITRILE; KETOPROFEN; METHANOL; PANTOPRAZOLE; ROFECOXIB; VALSARTAN;

ARTICLE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIODE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PARTICLE SIZE; SEPARATION TECHNIQUE; VALIDATION STUDY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INDICATORS AND REAGENTS; KETOPROFEN; OMEPRAZOLE; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SULFOXIDES; TETRAZOLES; VALINE;

EID: 33746242339     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cass QB, Degani ALG, Cassiano NM, Pedrazolli J (2002) Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography. J Chromatogr B 766: 153-160.
2. Daneshtalab N, Lewanczuk RZ, Jamali F (2002) High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B 766: 345-349.
3. Dvořák J, Hájková R, Matysová L, Nováková L, Koupparis MA, Solich P (2004) Simultaneous HPLC determination of ketoprofen and its degradation products in the presence of preservatives in pharmaceuticals. J Pharm Biomed Anal 36: 625-629.
4. FDA/CDER guidance, Bioanalytical Method Validation, May 2001.
5. González L, López JA, Alonso RM, Jiménez RM (2002) Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection J Chromatogr A 949: 49-60.
6. Kshirsagar NA (1994) Therapeutic drug monitoring. J Postgrad Med 40: 1-2.
7. Martín MJ, Pablos F, González AG (1999) Simultaneous determination of caffeine and non-steroidal anti-inflammatory drugs in pharmaceutical formulations and blood plasma by reversed-phase HPLC from linear gradient elution. Talanta 49: 453-459.
8. Reddy KVSRK, Babu JM, Dubey PK, Sekhar BC, Reddy GO, Vyas K (2002) Isolation and characterisation of process-related impurities in rofecoxib. J Pharm Biomed Anal 29: 355-360.
9. Shah VP, Midha KK, Dighe S, Mcgilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittsman KA, Spector S (1992) Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J Pharm Sci 81: 309-312.
10. Şatana E, Altinay Ş, Göger NG, Özkan SA, Şentürk Z (2001) Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 25: 1009-1013.
11. Tatar S, Saǧlik S (2002) Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J Pharm Biomed Anal 30: 371-375.
12. Woolf E, Fu I, Matuszewski B (1999) Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection. J Chromatogr B 730: 221-227.